Trials / Completed
CompletedNCT01566149
Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)
An Open-Label Study to Assess the Safety and Tolerability of Zenhale® (a Fixed-Dose Combination of Mometasone Furoate/Formoterol Fumarate Delivered by Metered Dose Inhaler) in 40 Subjects With Persistent Asthma (Protocol No. 206-00 [P08212])
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability \& effectiveness of 2 strengths of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in the treatment of persistent asthma in adults \& adolescents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI | Two oral inhalations per dose |
| DRUG | Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI | Two oral inhalations per dose |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2012-03-29
- Last updated
- 2024-05-24
- Results posted
- 2013-07-29
Source: ClinicalTrials.gov record NCT01566149. Inclusion in this directory is not an endorsement.